Zim Laboratories Limited — Important, 19-03-2025: Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals

ZIM Laboratories has announced a board meeting to discuss the grant of Marketing Authorization for its Dimethyl Fumarate 120 mg & 240 mg Modified Release Capsules in Portugal. This approval from INFARMED enhances ZIM’s commercial prospects, allowing for expedited approvals in other EU countries and the UK. The product, aimed at treating multiple sclerosis, utilizes proprietary technology and is bioequivalent to the innovator. The EU market for this treatment was valued at approximately USD 800 Mn in 2023, indicating strong growth potential. This update may generate a positive outlook among investors, reflecting the company’s strategic expansion into key markets.